Erythropoietin (EPO)

Medicina y Laboratorio

View Publication Info
 
 
Field Value
 
Title Erythropoietin (EPO)
Eritropoyetina (EPO)
 
Creator de los Ríos-Morales, Luz Adriana
Guevara-Arismendy, Natalia M.
Vizcaíno-Carruyo, Jennifer C.
Toro-Montoya, Ana Isabel
 
Description Erythropoietin (EPO) is a glycoprotein hormone produced mainly in the peritubular cells of the kidneys, which regulates erythrocyte production and differentiation. Erythropoietin synthesis is regulated by changes in oxygen availability, that is, the higher the oxygen, the lower the EPO production, and vice versa. EPO binds to receptors on CD34 + hematopoietic stem cells, promoting the activation of genes to stimulate their proliferation and differentiation into mature erythrocytes
La eritropoyetina (EPO) es una hormona glucoproteica producida principalmente en las células peritubulares de los riñones, que regula la producción y diferenciación eritrocitaria. La síntesis de eritropoyetina está regulada por cambios en la disponibilidad del oxígeno, es decir, a mayor cantidad de oxígeno, menor producción de EPO, y a la inversa. La EPO se une a los receptores en las células madre hematopoyéticas CD34+, promoviendo la activación de los genes para estimular su proliferación y diferenciación hasta eritrocitos maduros.
 
Publisher EDIMECO S.A.
 
Date 2020-09-29
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
 
Identifier https://medicinaylaboratorio.com/index.php/myl/article/view/342
10.36384/01232576.342
 
Source Medicina & Laboratorio; Vol. 24 No. 4 (2020): Octubre-Diciembre; 344-347
Medicina y Laboratorio; Vol. 24 Núm. 4 (2020): Octubre-Diciembre; 344-347
2500-7106
0123-2576
 
Language spa
 
Relation https://medicinaylaboratorio.com/index.php/myl/article/view/342/328
/*ref*/Beckman Coulter. Access EPO. Erythropoietin, ref A1636. California, USA: Beckman Coulter. Acceso 22 de agosto de 2020. Disponible en https://www.beckmancoulter.com/download/file/phxA88209K-EN_US/A88209K?type=pdf. 2. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 2019;94:133-143. https://doi.org/10.1002/ajh.25303. 3. Cullis JO. Diagnosis and management of anaemia of chronic disease: current status. Br J Haematol 2011;154:289-300. https://doi.org/10.1111/j.1365-2141.2011.08741.x. 4. Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, et al. Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC nephrology 2017;18:345-345. https://doi.org/10.1186/s12882-017-0688-1. 5. Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. J Clin Oncol 2019;37:1336-1351. https://doi.org/10.1200/jco.18.02142.
 
Rights https://creativecommons.org/licenses/by-nc-nd/4.0
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library